The group's principal activities are to conduct research, develop and produce collagenase abc enzyme. Collagenase abc, is an enzyme that digests collagen, the body's principal connective tissue. The drug is approved for topical enzymatic debridement of dermal ulcers (wounds), such as pressure ulcers and second and third degree burns. Collagenase abc enzyme powder is the active pharmaceutical ingredient of a topical ointment. The group has operations in North America, South America and Europe. Royalties accounted for 52% of 2002 revenues and collagenase abc enzyme, 48%.
